BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 9087280)

  • 1. [Cancer vaccine therapy using peptides derived from tumor-rejection antigens].
    Akiyoshi T
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):511-9. PubMed ID: 9087280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
    Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ; Parkinson DR; Marincola F
    J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
    Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Human tumor-rejection antigens and peptides from genes to clinical research].
    Itoh K; Yamana H; Shichijo S; Yamada A
    Nihon Geka Gakkai Zasshi; 2000 Sep; 101(9):612-7. PubMed ID: 11022676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
    Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
    Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs.
    Gomi S; Nakao M; Niiya F; Imamura Y; Kawano K; Nishizaka S; Hayashi A; Sobao Y; Oizumi K; Itoh K
    J Immunol; 1999 Nov; 163(9):4994-5004. PubMed ID: 10528204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.
    Wang RF; Johnston SL; Zeng G; Topalian SL; Schwartzentruber DJ; Rosenberg SA
    J Immunol; 1998 Oct; 161(7):3598-606. PubMed ID: 9759882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.
    Salazar-Onfray F; Nakazawa T; Chhajlani V; Petersson M; Kärre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R
    Cancer Res; 1997 Oct; 57(19):4348-55. PubMed ID: 9331097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides.
    Tsuda N; Murayama K; Ishida H; Matsunaga K; Komiya S; Itoh K; Yamada A
    J Orthop Res; 2001 May; 19(3):346-51. PubMed ID: 11398844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
    Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
    Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor rejection antigen and cancer immunotherapy].
    Matsutake T; Nakayama E
    Gan To Kagaku Ryoho; 1995 Nov; 22(13):1871-7. PubMed ID: 7487115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
    Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
    Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.